Latest Content

Jan Philipp Bewersdorf, MD, FACP, detailed findings from a meta-analysis and considerations for the use of luspatercept for anemia in lower-risk MDS.

David R. Wise, MD, PhD, discusses data from a phase 1b study of pasritamig plus docetaxel in mCRPC.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in March 2026.

A new study from researchers at The University of Texas MD Anderson Cancer Center shows that a specialized high-dose type of radiation delivery may improve outcomes in cholangiocarcinoma

GATA2 variants retain enhancer activity, alter differentiation, and may link inflammation to hematologic malignancy risk.

Rana R. McKay, MD, discusses data from the phase 4 OPTYX study of real-world relugolix in prostate cancer.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, head and neck cancer, breast cancer, prostate cancer, and leukemia.

The FDA grants full approval to brexu-cel in mantle cell lymphoma, grants priority review to a lirafugratinib NDA in FGFR2+ pretreated cholangiocarcinoma, and more.

Jennifer R. Brown, MD, PhD, discusses the FDA approval of acalabrutinib plus venetoclax for chronic lymphocytic leukemia and how it improves QOL.

Research found that adjuvant immunotherapy plus chemotherapy in stage 3 colon cancer was associated with a reduction in recurrence vs chemotherapy alone.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Sagar S. Patel, MD, discusses data from a retrospective analysis of Orca-T and PTCy for hematologic malignancies and its implications for the field.

CTIM-76 received fast track designation from the FDA for pretreated platinum-resistant ovarian cancer.